Network Meta-analysis of 14 oral Chinese patent medicines combined with Azithromycin in treatment of mycoplasma pneumonia in children.
10.19540/j.cnki.cjcmm.20210408.501
- Author:
Xun SUN
1
;
Xiao-Ying LING
2
;
Qiu-Yue XU
3
;
Ming-Chen JIANG
2
;
Bin YUAN
2
Author Information
1. Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing 210029, China Nanjing University of Chinese Medicine Nanjing 210029, China.
2. Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing 210029, China.
3. Nanjing University of Chinese Medicine Nanjing 210029, China.
- Publication Type:Meta-Analysis
- Keywords:
children;
mycoplasma pneumonia;
network Meta-analysis;
oral Chinese patent medicine
- MeSH:
Azithromycin;
Child;
China;
Drugs, Chinese Herbal;
Humans;
Network Meta-Analysis;
Nonprescription Drugs;
Pneumonia, Mycoplasma/drug therapy*;
Randomized Controlled Trials as Topic
- From:
China Journal of Chinese Materia Medica
2021;46(22):5958-5976
- CountryChina
- Language:Chinese
-
Abstract:
To systematically evaluate the clinical efficacy of 14 oral Chinese patent medicines combined with Azithromycin in the treatment of mycoplasma pneumonia in children with network Meta-analysis. Computer retrieval was performed for such databases as CNKI, VIP, Wanfang, CBM, PubMed, EMbase and Cochrane Library to screen out randomized controlled trials of oral Chinese patent medicines combined with Azithromycin in the treatment of mycoplasma pneumonia in children from the time of database establishment to September 2020. The included studies were evaluated by the Cochrane Risk Assessment tool. Stata 14.0 and Review Manager 5.3 software were used for data statistical analysis. A total of 60 RCTs were included in this study, involving 14 oral Chinese patent medicines. The efficacy ranking based on network Meta-analysis was as follows:(1)in terms of total effective rate, top five Chinese patent medicines in surface under the cumulative ranking curve(SUCRA) were Xiao'er Xiaoji Zhike Oral Liquid, Xiao'er Chiqiao Qingre Granules, Xiao'er Feike Granules, Pudilan Xiaoyan Oral Liquid and Lanqin Oral Liquid;(2)in terms of antifebrile time, top five Chinese patent medicines in SUCRA were Huaiqihuang Granules, Xiao'er Magan Granules, Xiao'er Kechuanling Granules/Oral Liquid, Shuanghuang-lian Oral Liquid for children and Xiao'er Xiaoji Zhike Oral Liquid;(3)in terms of cough disappearance time, top five Chinese patent medicines in SUCRA were Xiao'er Magan Granules, Huaiqihuang Granules, Xiao'er Chiqiao Qingre Granules, Xiao'er Feire Kechuan Oral Liquid and Xiao'er Kechuanling Granules/Oral Liquid;(4)in terms of rale disappearance time, top five Chinese patent medicines in SUCRA were Xiao'er Magan Granules, Huaiqihuang Granules, Xiao'er Feire Kechuan Oral Liquid, Shuanghuanglian Oral Liquid for children and Yupingfeng Granules. The results showed that on the basis of the use of Azithromycin, combined administration with oral Chinese patent medicines could improve the overall clinical efficacy in the treatment of mycoplasma pneumonia in children. However, due to the large differences in the quality and the number of included studies among various therapeutic measures, the ranking results of SUCRA of Chinese patent medicines need to be verified by high-quality multi-center, large-sample, randomized double-blind trials in the future.
